<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cimetidine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cimetidine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cimetidine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9265" href="/d/html/9265.html" rel="external">see "Cimetidine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12163" href="/d/html/12163.html" rel="external">see "Cimetidine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F151515"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cimetidine Acid Reducer [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866342"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Cimetidine [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1057349"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>
<li>
<span class="list-set-name">Histamine H<sub>2</sub> Antagonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F151543"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e06a2b0-8aba-4349-a56c-d40b3142a46e">Duodenal ulcer, treatment and maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Duodenal ulcer, treatment and maintenance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents &lt;16 years: Limited data available, efficacy results variable: Oral: 20 to 40 mg/kg/day in 3 to 4 divided doses for 4 to 8 weeks (maximum dose: 300 mg/dose), followed by 5 to 8 mg/kg/dose once daily at bedtime (maximum dose: 400 mg/dose) (Chiang 1989; Thomson 1983; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥16 years: Oral: 800 mg at bedtime or 400 mg twice daily or 300 mg 4 times daily for up to 8 weeks, followed by maintenance therapy of 400 mg once daily at bedtime (manufacturer's labeling). <b>Note:</b> Although treatment of active duodenal ulcers and maintenance therapy are included in the FDA manufacturer's labeling, use has fallen out of favor and in adults, experts suggest that cimetidine not be routinely used due to several cimetidine drug interactions and the preference for other options (eg, other histamine H<sub>2</sub> antagonists, proton pump inhibitors [PPIs]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c35c2d9c-ae53-47ab-a539-2ac2abeaf552">Gastric ulcer, active</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric ulcer, active:</b> Adolescents ≥16 years: Oral: 800 mg at bedtime or 300 mg 4 times daily for up to 8 weeks (manufacturer's labeling). <b>Note:</b> Although treatment of active gastric ulcers is included in the FDA manufacturer's labeling, use has fallen out of favor and in adults, experts suggest that cimetidine not be routinely used due to several cimetidine drug interactions and the preference for other options (eg, other histamine H<sub>2</sub> antagonists, PPIs).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d70158bf-5a0b-453d-9ae1-580dc5459992">Gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease (GERD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;16 years: Limited data available: Oral: 30 to 40 mg/kg/day in 4 divided doses; maximum dose: 400 mg/dose (AAP [Lightdale 2013]; Cucchiara 1989; NASPGHAN/ESPGHAN [Rosen 2018]; manufacturer's labeling). A pharmacokinetic modeling study suggests that the optimal dose for acid suppression is 10 mg/kg/dose every 6 hours and that some patients may need doses as high as 15 mg/kg/dose (Lambert 1992).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥16 years: Oral: 400 mg 4 times daily or 800 mg twice daily for 12 weeks (manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fe1c098-0767-49b7-87df-f3a4952757ba">Pathological hypersecretory conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥16 years: Oral: 300 mg 4 times daily; adjust dose to patient response; maximum daily dose: 2,400 mg<b>/day </b>(manufacturer's labeling). <b>Note:</b> Although treatment of pathological hypersecretory conditions is included in the FDA manufacturer's labeling, use has fallen out of favor and in adults, experts suggest that cimetidine not be routinely used due to several cimetidine drug interactions and the preference for other options (eg, other histamine H<sub>2</sub> antagonists, PPIs).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9ea90a8a-a2f9-4b8b-9295-98f89955dc9a">Sour stomach/Heartburn</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sour stomach/Heartburn (OTC labeling): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention:</i> Children ≥12 years and Adolescents: Oral: 200 mg daily up to 30 minutes prior to eating foods or beverages that cause heartburn (maximum daily dose: 400 mg/24 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relief of symptoms:</i> Children ≥12 years and Adolescents: Oral: 200 mg daily; maximum daily dose: 400 mg/24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084782"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Adolescents ≥16 years: Oral (manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate renal impairment:</i> There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe renal impairment:</i> 300 mg every 12 hours; may increase frequency with caution. When hepatic impairment is also present, further reductions in dosage may be necessary.</p></div>
<div class="block dohp drugH1Div" id="F51084783"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents ≥16 years: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Dosage adjustments may be needed in patients with both renal and hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F151520"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9265" href="/d/html/9265.html" rel="external">see "Cimetidine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="57b2690d-2e6b-47ae-87e7-f6f5ed2ef93f">Erosive esophagitis due to gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erosive esophagitis due to gastroesophageal reflux disease</b>
<b> (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Although a labeled indication, H<sub>2</sub>-receptor antagonists (eg, cimetidine) for the treatment of erosive esophagitis due to gastroesophageal reflux disease are not preferred due to the availability of proton pump inhibitors (ACG [Katz 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>400 mg 4 times daily or 800 mg twice daily for 12 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b24ffb30-7466-4c31-9437-62d98f7c42b8">Heartburn</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heartburn (OTC labeling):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention:</i>
<b>Oral:</b> 200 mg daily up to 30 minutes prior to eating foods or beverages that cause heartburn (maximum: 400 mg per 24 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relief of symptoms:</i>
<b>Oral:</b> 200 mg daily; maximum: 400 mg per 24 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6fef1f7c-57c6-4226-b257-b8b6de839621">Interstitial cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial cystitis (bladder pain syndrome) (off-label use):</b>
<b>Oral:</b> 200 mg 3 times daily or 300 to 400 mg twice daily (Dasgupta 2001; Seshadri 1994; Thilagarajah 2001).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fe1c098-0767-49b7-87df-f3a4952757ba">Pathological hypersecretory conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome [gastrinoma]) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although a labeled indication, clinical experience suggests that H<sub>2‑</sub>RAs (eg, cimetidine) are not preferred for controlling acid hypersecretion in pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome) due to the availability of proton pump inhibitors (Guarnotta 2018; Ito 2013; Tomassetti 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>300 mg 4 times daily; adjust dose to patient response; maximum 2.4 g/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2af7f7c-17b6-4ce5-b3f8-76af48f85574">Peptic ulcer disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peptic ulcer disease (duodenal or benign gastric ulcers) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although a labeled indication, current guidelines recommend proton pump inhibitors as standard of care for treatment of peptic ulcer disease rather than H<sub>2</sub>-receptor antagonists (eg, cimetidine) (ACG [Laine 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Duodenal ulcer, active:</i> Oral:</b> 300 mg 4 times daily, or 400 mg twice daily, or 800 mg once daily at bedtime for up to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Higher doses of 1.6 g once daily at bedtime for 4 weeks may be beneficial for patients with duodenal ulcers &gt;1 cm (defined endoscopically) who smoke ≥1 pack/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Duodenal ulcer, prophylaxis: </i>Oral: </b>400 mg once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Gastric ulcer, active:</i></b>
<b>Oral:</b> 300 mg 4 times daily or 800 mg once daily at bedtime for up to 8 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7e9db65-692c-4114-931f-7e81d2b23b54">Stress ulcer prophylaxis in critically ill patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress ulcer prophylaxis in critically ill patients (alternative agent) (off-label use): </b>
<b>Note: </b>Used as an alternative for proton pump inhibitors in critically ill patients with risk factors for GI bleeding (eg, coagulopathy, mechanical ventilation for &gt;48 hours, traumatic brain injury, history of GI ulceration or bleeding within past year, extensive burns) (SSC [Evans 2021]; Weinhouse 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral or NG tube:</b> 300 mg 4 times daily (ASHP 1999). Discontinue prophylaxis once risk factors have resolved (SSC [Evans 2021]; Weinhouse 2022).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991849"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Manufacturer's labeling:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate kidney impairment:</i> There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe kidney impairment:</i> 300 mg every 12 hours; may increase frequency with caution. When hepatic impairment is also present, further reductions in dosage may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Alternate recommendations (Aronoff 2007):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>GFR &gt;50 mL/minute:</i> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>GFR 10 to 50 mL/minute:</i> Administer 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>GFR &lt;10 mL/minute:</i> 300 mg every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hemodialysis:</i> Dose after dialysis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CRRT:</i> Administer 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Peritoneal dialysis:</i> 300 mg every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Geriatric patients ≥65 years: CrCl &lt;50 mL/minute: Reduce the dose because of risk of mental status changes (specific dosage adjustment is not provided (Beers Criteria [AGS 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">Stress ulcer prophylaxis in critically ill patients (off-label use): CrCl &lt;30 mL/minute: 300 mg twice daily (ASHP 1999).</p></div>
<div class="block doha drugH1Div" id="F50989143"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Dosage adjustments may be needed in patients with both kidney and hepatic impairment.</p></div>
<div class="block adr drugH1Div" id="F151479"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (2% to 4%), dizziness (1%), drowsiness (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Agitation, agranulocytosis, alopecia, anaphylaxis, anxiety, aplastic anemia, arthralgia, confusion, decreased white blood cell count, depression, disorientation, fever (Potter 1986), hallucination, hemolytic anemia (immune-based), hepatic fibrosis, hypersensitivity angiitis, hypersensitivity reaction, hypotension, impotence (Jensen 1983), increased serum transaminases, interstitial nephritis, myalgia, pancreatitis, pancytopenia, polymyositis (Watson 1983), psychosis, urinary retention, thrombocytopenia</p></div>
<div class="block coi drugH1Div" id="F151495"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to cimetidine or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food, vomiting with blood, or bloody or black stools, allergic to cimetidine or other acid reducers. Do not use with other acid reducers.</p></div>
<div class="block war drugH1Div" id="F151476"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Confusion: Rare cases of reversible confusion have been associated with cimetidine; usually in older or severely ill patients, or in patients with kidney or hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin B<sub>12</sub> deficiency: Prolonged treatment (≥2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment; dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunocompromised patients: May have increased risk of hyperinfection of strongyloidiasis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use caution in this age group due to risk of confusion and other CNS effects. Cimetidine should be avoided in those older adults with, or at risk of, delirium.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Serum creatinine/creatinine clearance estimates: Cimetidine can cause a transient and reversible rise in serum creatinine and/or decrease in CrCl (when using routine CrCl estimation formulas). This interference is likely due to competitive inhibition of cimetidine with creatinine for active tubular secretion and independent of an actual change in GFR. In patients with normal kidney function, the rise in serum creatinine may not be clinically apparent, but in patients with varying degrees of kidney impairment, this rise in serum creatinine may be more significant. Thus, treatment with cimetidine in patients with kidney failure may invalidate measurements of serum creatinine and estimates of CrCl (Andreev 1999; Larsson 1980). However, CrCl estimation formulas, such as Cockcroft-Gault, are known to overestimate actual GFR, particularly in patients with kidney impairment, and use of cimetidine has been explored clinically to improve the accuracy of CrCl estimates in these patients (Choi 1993; Van Acker 1992).</p>
<p style="text-indent:-2em;margin-left:4em;">• OTC labeling: When used for self-medication (OTC), notify health care provider before use if any of the following are present: frequent chest pain; frequent wheezing particularly with heartburn; nausea/vomiting; unexplained weight loss; stomach pain; heartburn &gt;3 months; heartburn with light-headedness, sweating, or dizziness; chest pain or shoulder pain with shortness of breath; sweating or pain that spreads to arms, neck, or shoulders; light-headedness. Stop use and notify health care provider if heartburn continues or worsens, stomach pain continues, or if use is required &gt;14 days.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878385"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H<sub>2</sub> receptor antagonists; however, a causal relationship with cimetidine has not been demonstrated. A cohort analysis including more than 11,000 neonates reported an association between H<sub>2</sub> blocker use and an increased incidence of necrotizing enterocolitis (NEC) in very low birth weight (VLBW) neonates (Guillet 2006). An approximate sixfold increase in mortality, NEC, and infection (ie, sepsis, pneumonia, urinary tract infection) was reported in patients receiving another H<sub>2</sub> blocker, ranitidine, in a cohort analysis of 274 VLBW neonates (Terrin 2012).</p></div>
<div class="block foc drugH1Div" id="F151488"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg/6.67 mL (6.67 mL [DSC]); 300 mg/5 mL (5 mL [DSC], 237 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cimetidine Acid Reducer: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg, 300 mg, 400 mg, 800 mg</p></div>
<div class="block geq drugH1Div" id="F151472"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F151497"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cimetidine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $3.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $1.61 - $2.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $2.61 - $3.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $5.02 - $6.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866343"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg, 300 mg, 400 mg [DSC], 600 mg [DSC], 800 mg</p></div>
<div class="block exp drugH1Div" id="F10806351"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Commercial oral solution is available (strength expressed as base: 60 mg/mL).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>60 mg/mL oral suspension</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 60 mg/mL oral suspension may be made with tablets. Place twenty-four 300 mg tablets in 5 mL of sterile water for ~3 to 5 minutes to dissolve film coating. Crush tablets in a mortar and reduce to a fine powder. Add 10 mL of glycerin and mix to a uniform paste; mix while adding Simple Syrup, NF in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label "shake well" and "refrigerate." Stable for 17 days.</p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52612421"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food; do not administer simultaneously with antacids.</p></div>
<div class="block adm drugH1Div" id="F151492"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with meals. For stress ulcer prophylaxis in critically-ill patients (off-label use), may administer via NG tube (Rhodes 2017).</p></div>
<div class="block sts drugH1Div" id="F151508"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at room temperature. Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53566065"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Short-term and maintenance treatment of duodenal ulcers; short-term treatment of active benign gastric ulcers; treatment of gastroesophageal reflux disease (GERD); treatment of pathologic hypersecretory conditions (eg, Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas) (All indications: FDA approved in ages ≥16 years and adults); relief and prevention of heartburn associated with acid indigestion and sour stomach (OTC product: FDA approved in ages ≥12 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although duodenal and gastric ulcer treatment and treatment of pathological hypersecretory conditions are included in the FDA manufacturer's labeling, use has fallen out of favor and in adults, experts suggest that cimetidine not be routinely used due to several cimetidine drug interactions and the preference for other options (eg, other histamine H<sub>2</sub> antagonists, proton pump inhibitors [PPIs]).</p></div>
<div class="block mst drugH1Div" id="F151577"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cimetidine may be confused with simethicone</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F151562"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3, P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak), CYP2C19 (weak), CYP2D6 (weak), CYP3A4 (weak), OCT1, OCT2</p></div>
<div class="block dri drugH1Div" id="F151481"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib.  Management: Give acalabrutinib capsules 2 hours before a histamine H2 receptor antagonist (H2RA). No action is required if acalabrutinib tablets are coadministered with H2RAs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: Cimetidine may increase the serum concentration of ALfentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: Cimetidine may increase the serum concentration of Amiodarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: Cimetidine may enhance the adverse/toxic effect of Atorvastatin. Specifically, there is a theoretical potential for enhanced effects on reducing endogenous steroid activity. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Systemic): Cimetidine may increase the serum concentration of Azelastine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Histamine H2 Receptor Antagonists may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists (H2RAs) more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromazepam: Cimetidine may increase the serum concentration of Bromazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers: Cimetidine may increase the serum concentration of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carmustine: Cimetidine may enhance the myelosuppressive effect of Carmustine.  Management: Consider alternatives to cimetidine in patients receiving carmustine. If the combination cannot be avoided, monitor for enhanced carmustine myelotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlordiazePOXIDE: Cimetidine may increase the serum concentration of ChlordiazePOXIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: Cimetidine may increase the serum concentration of Chlormethiazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: Cimetidine may increase the serum concentration of Chloroquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: Cimetidine may increase the serum concentration of Cisapride.  Management: Consider alternatives to cimetidine. If this combination cannot be avoided, monitor for toxic effects of cisapride, particularly QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: Cimetidine may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with cimetidine. Patients using this combination should be monitored closely for evidence of citalopram toxicity (eg, serotonin syndrome, QT prolongation).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Weak) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OCT2 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Cimetidine may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dacomitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Dacomitinib.  Management: Administer dacomitinib at least 6 hours before or 10 hours after an histamine H2-receptor antagonist (H2RA).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dalfampridine: OCT2 Inhibitors may increase the serum concentration of Dalfampridine.  Management: Consider alternatives to this combination. Carefully weigh the risk of seizures against the benefit of combining OCT2 inhibitors with dalfampridine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Cimetidine may increase the serum concentration of Dofetilide. This is likely via inhibition of dofetilide renal tubular secretion (primarily) and inhibition of dofetilide metabolism. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Cimetidine may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: Cimetidine may increase the serum concentration of Enoxacin. Cimetidine may decrease the serum concentration of Enoxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EpiRUBicin: Cimetidine may increase the serum concentration of EpiRUBicin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): Cimetidine may increase the serum concentration of Erythromycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: Cimetidine may increase the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: Cimetidine may increase the serum concentration of Flunitrazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: Cimetidine may increase the serum concentration of Fluorouracil Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FLUoxetine: Cimetidine may increase the serum concentration of FLUoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Cimetidine may enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Cimetidine may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Consider using an alternative H<sub>2</sub>-antagonist to avoid this interaction. Monitor for toxic effects of hydantoin antiseizure drugs if cimetidine is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or 6 hours after administration of a histamine H2 receptor antagonist (H2RA), and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">GlipiZIDE: Cimetidine may increase the serum concentration of GlipiZIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: Cimetidine may increase the serum concentration of Hydroxychloroquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Histamine H2 Receptor Antagonists may decrease serum concentrations of the active metabolite(s) of Infigratinib. Histamine H2 Receptor Antagonists may decrease the serum concentration of Infigratinib.  Management: Avoid coadministration of infigratinib with histamine receptor antagonists (H2RAs) or other gastric acid-lowering agents. If H2RAs cannot be avoided, administer infigratinib 2 hours before or 10 hours after administration of H2RAs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Histamine H2 Receptor Antagonists may increase the serum concentration of Itraconazole. Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole.  Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any histamine H2 receptor antagonists (H2RAs). Exposure to Tolsura brand itraconazole may be increased by H2RAs; consider itraconazole dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer ketoconazole with an acidic beverage (eg, non-diet cola) and monitor for reduced efficacy if concomitant use with a H2RA is required. Increases in ketoconazole dose may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir.  Management: Administer H2 receptor antagonist doses less than or comparable to famotidine 40 mg twice daily simultaneously or 12 hours prior to ledipasvir. The effect of administering H2 receptor antagonists at other time intervals is unknown and  not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Histamine H2 Receptor Antagonists may decrease the absorption of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): Cimetidine may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Topical): Cimetidine may increase the serum concentration of Lidocaine (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a weak CYP2C19 inhibitor. For those stable on mavacamten who are initiating a weak CYP2C19 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: Cimetidine may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: Cimetidine may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Cimetidine may increase the serum concentration of MetFORMIN.  Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (including lactic acidosis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: Cimetidine may increase the serum concentration of Mirtazapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moclobemide: Cimetidine may increase the serum concentration of Moclobemide.  Management: Consider using alternative agents to increase gastric pH in order to avoid this interaction. If combined, a moclobemide dose reduction of 50% may be necessary, and patients should be monitored for increased moclobemide effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Histamine H2 Receptor Antagonists may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption.  Management: Administer neratinib at least 2 hours before or 10 hours after administration of a histamine H2 receptor antagonist to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib.  Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Histamine H2 Receptor Antagonists may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: Cimetidine may increase the serum concentration of Ornidazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PARoxetine: Cimetidine may increase the serum concentration of PARoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: Cimetidine may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Pexidartinib.  Management: Administer pexidartinib 2 hours before or 10 hours after histamine H2 receptor antagonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pilsicainide: Cimetidine may increase the serum concentration of Pilsicainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Cimetidine may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent cimetidine unless potential benefits outweigh the risks of possible inadequate response. If concomitant use cannot be avoided, monitor steady state posaconazole trough levels and monitor for evidence of decreased antifungal effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: Cimetidine may increase the serum concentration of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: Cimetidine may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procainamide: Cimetidine may increase the serum concentration of Procainamide.  Management: Consider an alternative H2-receptor antagonist in patients taking procainamide. If combined, monitor for increased therapeutic effects/toxicity of procainamide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: Cimetidine may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Cimetidine may increase the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: Cimetidine may increase the serum concentration of QuiNINE.  Management: Consider using an alternative H2-receptor antagonist (eg, ranitidine) instead of cimetidine due to a lower interaction risk. If combined, monitor patients closely for signs and symptoms of quinine toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists (H2RAs) at least 12 hours before or 4 hours after oral rilpivirine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risedronate: Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: Cimetidine may increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. Cimetidine may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir.  Management: Consider alternatives to this combination for patients taking the Invirase formulation of saquinavir. No action beyond standard clinical care measures is required for patients taking the Fortovase formulation of saquinavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and H2 receptor antagonists should be avoided. If coadministration cannot be avoided, selpercatinib should be administered 2 hours before or 10 hours after H2 receptor antagonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Cimetidine may increase the serum concentration of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Histamine H2 Receptor Antagonists may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: Cimetidine may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">TOLBUTamide: Cimetidine may increase the serum concentration of TOLBUTamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Cimetidine may increase the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Cimetidine may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cimetidine may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Avoid coadministration of cimetidine and vitamin K antagonists. If unavoidable, monitor for increased effects of vitamin K antagonists when cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: Cimetidine may increase the serum concentration of Zaleplon.  Management: The initial dose of zaleplon should be limited to 5 mg in patients taking cimetidine. Monitor patients for increased zaleplon effects/toxicities (ie, sedation, CNS depression) when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ZOLMitriptan: Cimetidine may increase the serum concentration of ZOLMitriptan.  Management: Limit the maximum single dose of zolmitriptan to 2.5 mg, not to exceed 5 mg in 24 hours, when coadministered with cimetidine.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F151511"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Prolonged treatment (≥2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>
<div class="block pri drugH1Div" id="F3338825"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cimetidine crosses the placenta (Howe 1981). Histamine H<sub>2</sub> antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD), as well as gastric and duodenal ulcers during pregnancy (Cappell 2003; Richter 2003). Histamine H<sub>2</sub> antagonists may be used for aspiration prophylaxis prior to cesarean delivery (ASA 2007).</p></div>
<div class="block mopp drugH1Div" id="F53566035"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, gastric pH, occult blood with GI bleeding; renal function</p></div>
<div class="block pha drugH1Div" id="F151475"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitive inhibition of histamine at H<sub>2</sub> receptors of the gastric parietal cells resulting in reduced gastric acid secretion, gastric volume and hydrogen ion concentration reduced</p></div>
<div class="block phk drugH1Div" id="F151494"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 80% reduction in gastric acid secretion for 4 to 5 hours after 300 mg dose</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Children and Adolescents: 1.23 ± 0.45 L/kg (Lloyd 1985b); Adults: 1 to 1.5 L/kg (Somogyi 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 20% (Somogyi 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Partially hepatic, forms metabolites (Somogyi 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~60% to 70% (Somogyi 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Neonates: 3.6 hours (Lloyd 1985a); Children and Adolescents: 1.39 ± 0.25 hours (Lloyd 1985b); Adults: ~2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 0.75 to 1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (48% as unchanged drug); feces (2%) (Somogyi 1983)</p></div>
<div class="block phksp drugH1Div" id="F51220837"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Drug accumulation may occur in patients with severe kidney failure.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F151498"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adiatin | Apo cimetidine | Cimedine | Cimetag | Citius | Tagamet</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tagamet | Ulcerfen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cimetag | Cimetidin genericon pharma | Neutromed | Neutronorm | Sodexx cimetidin | Ulcometin | Ulcostad</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cimehexal | Cimetidine-bc | Cimetimax | Magicul | Sbpa cimetidine | Sigmetadine | Tagamet</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acinil | Altramet | Apomed | Dimet | Histodil | Ulmet</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cimetidine Eurogenerics | Cimetidine ratiopharm | Cimetidine teva generics belgium | Cimetimed | Tagamet | Topcimet</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cimetidin | Tagamet</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cimedax | Cimetidan | Cimetidina | Cimetilab | Cimetinax | Cimetival | Cimeton | Cintidina | Climatidine | Duomet | Furp cimetidina | Gastidin | Gastrocine | Genodine | Novacimet | Pristonal | Prometidine | Stomakon | Stomet | Tagaliv | Tagamet | Tagamil | Tranimet | Ulcedine | Ulcenax | Ulcenon | Ulceracid | Ulcimet | Ulcinax | Ulcitag | Ulcitrat</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cimetidin-mepha | Tagamet</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo cimetidine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cimetidine and Sodium Chloride | Fu xin | Ghangfu you shu | Tagamet | Tai wei mei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cimetidina | Cimetidina mk | Convenal | Tagamet | Ulset</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo cimetidine | Belomet | Cimetidin | Cimetin | Lock | Primamet</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Azucimet | Cim lich | Cime | Cime abz | Cime puren | Cime sanorania | Cimebeta | Cimehexal | Cimemerck | Cimetidin | Cimetidin al | Cimetidin vp | Cimsigma | Ciuk | Dura h2 | H2 blocker | Sigacimet | Tagamet | Ulcolind h | Ulcubloc</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Tagamet</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cimetidina | Cimetin | Gastromet | Ulcemet</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Acinil | Cimesan | Cimetidin | Histodil | Primamet | Tsimetidiin | Ulcomet</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acidnor | Histadil | Tagamet</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fremet | Gastro h2 lesvi | Tagamet</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Cimet</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Acinil | Asiloc | Tagamet | Ulcur</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cimetidine g gam | Cimetidine gnr | Cimetidine merck | Cimetidine ratiopharm | Cimetidine rpg | Cimetidine teva | Tagamet</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Acitak | Cimetidine almus | Cimetidine arrow | Cimetidine berk | Cimetidine cox | Cimetidine dc | Cimetidine kent | Cimetidine sandoz | Galenamet | Peptimax | Phimetin | Tagadine | Tagamet | Ultec | Zita</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alkastom | Besidin | Grinolon | Tagamet | Tamper</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Altramet | Apo cimetidine | Axcel Cimetidine | Bigacon | Cementin | Cimedin | Cimedine | Cimeldine | Cimeta | Cimetidine Sunward | Cimulcer | Citidine | Clinimet | Defense | Gastab | Gastidine | Ginomin | Lotidine | Maritidine | Neo ulcergen | Neutronorm | Nulcer | Sanwell | Shintamet | Simaglen | Stomcap 1 | Syncomet | Tagamet | Taladine | Timet | Ulcergen | Ulcerin | Ulcermet | Ulcime | Ulcomet | Ulsikur | Ultec | Ultipus | Wetidine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cimehexal | Histodil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Benomet-300 | Cimet | Cimexol | Corsamet | Decamet | Licomet | Magicul | Nulcer | Omekur | Ramet | Sanmetidin | Simetidin | Tagamet | Tobymet | Ulcumet | Ulsikur | Xepamet</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cedine | Cimagen | Cimeldine | Galenamet | Geramet | Pinamet | Tagamet</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cemidin | Cimetag | Cimi | Tagamet</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alucim | Tagamed</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Biomag | Brumetidina | Cimetidina | Dina | Eureceptor | Notul | Tagamet | Temic | Ulcedin | Ulcodina | Ulcomedina | Ulis</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cimedine | Tagamet</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alukamet | Amuisan | Asmedin | Astrofen taiyo | Cilcar z | Cimeron | Cimetidine | Cimetidine hexal | Cimetidine tsuruhara | Cimetiparl | Cimetiran | Cmetiparl | Cylock | Cystamet | Dancart | Dancart chemiphar | Dansul | Esmeralda | Gasfellan | Gasfellon | Gastirine | Gastromet | Icrol | Ishimet | Lafcedin | Masuberan | Phardine mita | Roian c | Starcel | Stomatidin | Tagamet | Tagamet glaxosmithkline | Tagamet sumitomo | Taigastron | Takamigin c takata | Tiekapto | Togast | Ulcermec | Ulchyone</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cemet | Cimet | Labcimet | Micro cimetidine | Ulmet</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alvogen cimetidine | Aprogen cimetidine | Arlico cimetidine | Austidine | Bc cimetidine | Celmedine | Cigamet | Cignatin | Cimeridine | Cimeron | Cimet | Cimetadine | Cimeten | Cimetid | Cimetidine daewoo | Cimetidine myungmoon | Cimetidine woori | Cimetin | Cimetine | Cimtin | Ciradine | Cismetin | Citidine | Citin | Citine | Citron | Cl pharm cimetidine | Cmg cimetidine | Cmt | Cytin | Dongkoo cimetidine | Drimedine | Dualmet | Emetin | Etex cimetidine | Fanimet | Gl cimetidine | H 2b | H-2 | Hanlim cimetidine | Hastin | Himetine | Hlb cimetidine | Humetin | Huons cimetidine | Js cimetidine | Jungwoo cimetadine | Kms cimetidine | Kukje cimetidine | Magacidine | Meticon | Metidin | Metirin | Nelson cimetidine | Neutronorm | Newcime | Newmetidine | Newsime | Pharma cimetidine | Pharmgen cimetidine | Sama cimetidin | Signatin | Sinil cimetidine | Soctin | Somatin | Sulumetin | Tagamet | Tagatin | Tagetidin | Tagma | Tagmatin | Tagmetin | Taiguk cimetidine | Thrumetin | Trimetin | Ulcimet | Ulcomet | Ultamet | Union cimetidine | Wilpidin | Youngil cimetidine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo cimetidine | Tagamet</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo cimetidine | Cimetril | Neutronorm | Tagamet</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Acinil | Apo cimetidine | Belomet | Cimehexal | Cimesan | Cimetidin | Histodyl | Novo cime | Primamet | Tagamet</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cimehexal | Cimetidine Eurogenerics | Tagamet</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acinil | Apo cimetidine | Belomet | Cimbene | Cimehexal | Cimesan | Cimetidin | Cimetidin acis | Cimetidin Stada | Histodyl | Novo cime | Primamet | Tagamet</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Adiatin | Antagon h2 | Apo-cimetine | Tagamet | Ulcemat | Ulcestop</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Beamat | Cimetase | Colimet | Columina | Gastrodina | Gentiden | Sinegastrin | Tagamet | Ulcedine | Ulcerim c | Ulogen h-2 | Ulpax-cimetidina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo cimetidine | Axcel Cimetidine | Cimidine | Cimulcer | Duotric | Dynamet | Hamitag | Histodil | Shintamet | Tagamet | Tymidin | Ulcidine | Xepamet</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Chimexbon cimetidine | Cimec | Cinamodine | Citimed | Galen's cimetidine | Gasrol | Jopan cimetidine | Kadine | Mayadine | Me cure's cimetidine | New divine cimetidine | Nkoyo cimetidine | Octidime | Ordine | Rajcimeti | Stomprozol | Surelife cimetidine | Tacmed | Tardine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Tagamet</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Acinil | Cimal | Cimetid | Cimetidin | Cimetidin accord | Cimetidin acis | Cimetidin al | Cimetidine aa pharma | Cimetidine cf | Cimetidine mylan | Gastrobitan | Tagamet</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo cimetidine | Cytine | Tagamet</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Tagamet | Ulcimet</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Antag | Ciclem | Cimedin | Cimetidine Am-Europharma | Duogastril | Getidin | Montidin | Sermet | Shintamet | Tagamet | Ulcenon | Zymet</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acidil | Acimet | Agamid | Altramet | Arimet | Bacimet | Cid | Cidin | Cimepha | Cimet | Cimetamat | Cimirax | Cimizan | Cinil | Citadine | Citam | Contracid | Dozamet | Drape | Endonil | Eromet | Fovomet | Imetide | Neutronorm | Normacid | Phardine | Rakamet | Semag | Semidine | Tagamet | Ul-get | Ulcedine | Ulceloc | Ulcemet | Ulcerex | Ulcerine | Ulcet | Ulcetag | Ulsacure | Vasimet | Venopax | Wilcimet | Zemet</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Altramet | Belomet | Cimetidin | Cimetidine | Histodil | Tagamet</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cimetidine | Cimetidine in sodium chloride | Heartburn Relief | Tagamet | Tagamet hb</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cim | Cimetidina Sanofi | Evicer | Tagamet</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cimedine | Cimetag</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cimedine | Cimetidin | Cimetidina arena</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cimetidin | Histodyl | Primamet</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cimedine | Tagamet</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo cimetidine | Axcel Cimetidine | Cementin | Cimetidine Sunward | Citidine | Erlmetin | Himetin | Shintamet | Tagamet | Ulsikur | Xepamet</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Altramet | Belomet</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Apo cimetidine | Belomet | Primamet</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aidar | Alserine | Apo cimetidine | Bismet | Brumetidina | Cencamat | Chintamet | Ciamet | Cidimet | Cidine | Cimag | Cimax | Cimeca | Cimedin | Cimedine | Cimet | Cimet-p | Cimetin | Cimetine | Cimetstar | Cimulcer | Citadine | Citamet | Citidine | Citimet | Citius | Clinimet | Cmd | Cocidine | Cymet | Cytomet | Duodin | Duotric | G.i | Gastacil | Gastridine | Gastrodin | Homet | Iwamet | K.b.cymedin | Lagamet | Manomet | Medine | Mergamet | Metadine | Metamet | Metidine F | Milamet | Mogamet | Neutronorm | Norcidin | Pantidine | Pat Cimet | Peptica | Peptidine | Peptil | Peptimet | Pipcimet | Pondarmett | Promet | Pybumet | Rinadine | Rudine | Seatidine | Sertidine | Servicimet | Siamidine | Sigamet | Silmet | Simaglen | Simex | Sincimet | Sinomet | Stomedine | Tacamac | Tacidine | Tadine | Tagadine | Tagamet | Tagapro | Tamed | Tametab | Temet | Tisomet | Tymet | U-cimet | Ulcacin | Ulcemet | Ulcerine | Ulcimet | Ulcine | Ulsamet | Umamett | Vescidine | Zolintab</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cimedine | Metracine | Tagamet</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Simetin | Tagamet</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Acinil | Agastrin | Anulcus | Apo cimetidine | Brumetidina | C.m.t. | Ciketin | Cimedin | Cimedine | Cimefine | Cimenice | Cimeron | Cimet | Cimetin | Cimetine | Cimewei | Cimewell | Cimewet | Cimidin | Cinulcus | Citamet | Citidine | Citius | Civigen | Ciwei | Ciweitin | Ciwetim | Ciwetin | Ciwidine | Ciyanlin | Comgamet | Cowemin | Cystamet | Da con Wei | Defense | Derziqu | Duocer | Fanimet | Fastop | Gastomet | Gastrodin | Gawei | Himetin | Hou We Ming | Iscan | Koweishu | Ku-We-Rin | Megato | N-Way | Nurodin | P.U.N | Paiewell | Paoweian | Pawegon | Potence | Pouwepin | Powegon | Royamet | Safeway | Sanwell | Shuful | Sigamet | Stogamet | Suweilin | Suwelin | Swega | Tacreton | Tagamet | Tagamin | Tagasone | Tagawei | Tailiwell | Tamedin | Tamedine | Taweimin | Tawemet | Tigawet | Ulcestop | Weibau | Weicolin | Weisdin | Weisu | Wellcome | Wergen | Wetidine | Wijeton | Wintidine | Zukei</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cimehexal | Cimetidin | Histodyl | Primamet</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agocim | Astidin | Recim</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Amipylo | Biogastrol | Cimetidina | Fisiol | Ulcimet</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cavimet | Cimetidina | Cimetin | Cimetix | Gadol | Iscaten | Tagamet</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aci-med | Acidown | Adco-cimetidine | Apo cimetidine | Berk cimetidine | Bio cimetidine | Cimlok | Cinadine | Cymi | Hexamet | Lenamet | Micro-cimetidine | Norton-cimetidine | Rolab-cimetidine | Secadine | Tagamet</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cimedin | Cimet | Ulcidin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Adco-cimetidine | Bio cimetidine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17413923">
<a name="17413923"></a>American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. <i>Anesthesiology</i>. 2007;106(4):843-863.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/17413923/pubmed" id="17413923" target="_blank">17413923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10475992">
<a name="10475992"></a>Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? <i>J Intern Med</i>. 1999;246(3):247-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/10475992/pubmed" id="10475992" target="_blank">10475992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10690219">
<a name="10690219"></a>ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. <i>Am J Health Syst Pharm.</i> 1999;56(4):347-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/10690219/pubmed" id="10690219" target="_blank">10690219</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Avery GB, Fletcher MA, MacDonald MG, eds. <i>Neontatology - Pathophysiology and Management of the Newborn</i>. 4th ed. Philadelphia, PA: Lippincott Company; 1994.</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al, eds. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7779462">
<a name="7779462"></a>Burkhart KK, Janco N, Kulig KW, et al, “Cimetidine as Adjunctive Treatment for Acetaminophen Overdose,” <i>Hum Exp Toxicol</i>, 1995, 14(3):299-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/7779462/pubmed" id="7779462" target="_blank">7779462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16651285">
<a name="16651285"></a>Canani RB, Cirillo P, Roggero P, et al; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. <i>Pediatrics</i>. 2006;117(5):e817-e820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/16651285/pubmed" id="16651285" target="_blank">16651285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12635419">
<a name="12635419"></a>Cappell MS. Gastric and duodenal ulcers during pregnancy. <i>Gastroenterol Clin North Am</i>. 2003;32(1):263-308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/12635419/pubmed" id="12635419" target="_blank">12635419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2709247">
<a name="2709247"></a>Chiang BL, Chang MH, Lin MI, et al. Chronic duodenal ulcer in children: clinical observation and response to treatment. <i>J Pediatr Gastroenterol Nutr</i>. 1989;8(2):161-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/2709247/pubmed" id="2709247" target="_blank">2709247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8268144">
<a name="8268144"></a>Choi KC, Lee J, Kim SW, et al. Cimetidine improves the accuracy of creatinine clearance as an indicator for glomerular filtration rate. <i>Korean J Intern Med</i>. 1993;8(1):28-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/8268144/pubmed" id="8268144" target="_blank">8268144</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cimetidine tablets (prescribing information). Morgantown, WV: Mylan Pharmaceuticals Inc; August 2019.</div>
</li>
<li>
<div class="reference">
                  Cimetidine oral solution (prescribing information). Greenville, SC: Pharmaceutical Associates Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2651632">
<a name="2651632"></a>Cucchiara S, Gobio-Casali L, Balli F, et al. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. <i>J Pediatr Gastroenterol Nutr</i>. 1989;8(2):150-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/2651632/pubmed" id="2651632" target="_blank">2651632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6385868">
<a name="6385868"></a>Cucchiara S, Staiano A, Romaniello G, et al. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. <i>Arch Dis Child</i>. 1984;59(9):842-847.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/6385868/pubmed" id="6385868" target="_blank">6385868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11488726">
<a name="11488726"></a>Dasgupta P, Sharma SD, Womack C, Blackford HN, Dennis P. Cimetidine in painful bladder syndrome: a histopathological study. <i>BJU Int</i>. 2001;88(3):183-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/11488726/pubmed" id="11488726" target="_blank">11488726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fennerty MD and Higbee M, “Drug Therapy of Gastrointestinal Disease,” <i>Geriatric Pharmacology</i>, Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 585-608.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8136667">
<a name="8136667"></a>Garcia Rodriguez LA and Jick H, “Risk of Gynaecomastia Associated With Cimetidine, Omeprazole, and Other Antiulcer Drugs,” <i>BMJ</i>, 1994, 308(6927):503-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/8136667/pubmed" id="8136667" target="_blank">8136667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29019150">
<a name="29019150"></a>Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, Faggiano A; NIKE group. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? <i>Endocrine</i>. 2018;60(1):15-27. doi:10.1007/s12020-017-1420-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/29019150/pubmed" id="29019150" target="_blank">29019150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16390920">
<a name="16390920"></a>Guillet R, Stoll BJ, Cotten CM, et al, "Association of H<sub>2</sub>-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants," <i>Pediatrics</i>, 2006, 117(2):137-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/16390920/pubmed" id="16390920" target="_blank">16390920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AUA.2014">
<a name="AUA.2014"></a>Hanno PM, Burks DA, Clemens JQ, et al; American Urological Association Education and Research Inc. American Urological Association guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Published 2011. Updated December 5, 2014. Accessed March 17, 2020. https://www.auanet.org/guidelines/interstitial-cystitis-(ic/bps)-guideline
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AUA.2022">
<a name="AUA.2022"></a>Hanno PM, Burks DA, Clemens Q, et al; American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. https://www.auanet.org/guidelines-and-quality/guidelines/diagnosis-and-treatment-interstitial-of-cystitis/bladder-pain-syndrome-(2022). Published 2011. Updated 2022. Accessed August 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7246987">
<a name="7246987"></a>Howe JP, McGowan WA, Moore J, McCaughey W, Dundee JW. The placental transfer of cimetidine. <i>Anaesthesia</i>. 1981;36(4):371-375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/7246987/pubmed" id="7246987" target="_blank">7246987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7653194">
<a name="7653194"></a>Inoue A, Teramae H, Hisa T, et al, “Fixed Drug Eruption Due to Cimetidine,” <i>Acta Derm Venereol</i>, 1995, 75(3):250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/7653194/pubmed" id="7653194" target="_blank">7653194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23363383">
<a name="23363383"></a>Ito T, Igarashi H, Uehara H, Jensen RT. Pharmacotherapy of Zollinger-Ellison syndrome. <i>Expert Opin Pharmacother</i>. 2013;14(3):307-321. doi:10.1517/14656566.2013.767332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/23363383/pubmed" id="23363383" target="_blank">23363383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6835285">
<a name="6835285"></a>Jensen RT, Collen MJ, Pandol SJ, et al. Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. <i>N Engl J Med</i>. 1983;308(15):883-887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/6835285/pubmed" id="6835285" target="_blank">6835285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18789939">
<a name="18789939"></a>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, “American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,” <i>Gastroenterology</i>, 2008, 135(4):1383-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/18789939/pubmed" id="18789939" target="_blank">18789939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34807007">
<a name="34807007"></a>Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/34807007/pubmed" id="34807007" target="_blank">34807007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23419381">
<a name="23419381"></a>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2013;108(3):308-328; quiz 329. doi:10.1038/ajg.2012.444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/23419381/pubmed" id="23419381" target="_blank">23419381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1670987">
<a name="1670987"></a>Koren G and Zemlickis DM, “Outcome of Pregnancy After First Trimester Exposure to H<sub>2</sub>-Receptor Antagonists,” <i>Am J Perinatol</i>, 1991, 8(1):37-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/1670987/pubmed" id="1670987" target="_blank">1670987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3662179">
<a name="3662179"></a>Krenzelok EP, Litovitz T, Lippold KP, et al, “Cimetidine Toxicity: An Assessment of 881 Cases,” <i>Ann Emerg Med</i>, 1987, 16(11):1217-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/3662179/pubmed" id="3662179" target="_blank">3662179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929377">
<a name="33929377"></a>Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. <i>Am J Gastroenterol. </i>2021;116:899–917. doi:10.14309/ajg.0000000000001245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/33929377/pubmed" id="33929377" target="_blank">33929377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24327038">
<a name="24327038"></a>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/24327038/pubmed" id="24327038" target="_blank">24327038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1538302">
<a name="1538302"></a>Lambert J, Mobassaleh M, and Grand RJ, “Efficacy of Cimetidine for Gastric Acid Suppression in Pediatric Patients,” <i>J Pediatr</i>, 1992, 120(3):474-478.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/1538302/pubmed" id="1538302" target="_blank">1538302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28242110">
<a name="28242110"></a>Lanas A, Chan FKL. Peptic ulcer disease. <i>Lancet</i>. 2017;390(10094):613-624. doi:10.1016/S0140-6736(16)32404-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/28242110/pubmed" id="28242110" target="_blank">28242110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7001858">
<a name="7001858"></a>Larsson R, Bodemar G, Kågedal B, Walan A. The effects of cimetidine (<i>Tagamet)</i> on renal function in patients with renal failure. <i>Acta Med Scand</i>. 1980;208(1-2):27-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/7001858/pubmed" id="7001858" target="_blank">7001858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629618">
<a name="23629618"></a>Lightdale JR, Gremse DA; Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. <i>Pediatrics</i>. 2013;131(5):e1684-1695. doi:10.1542/peds.2013-0421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/23629618/pubmed" id="23629618" target="_blank">23629618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3884305">
<a name="3884305"></a>Lloyd CW, Martin WJ, and Taylor BD. The pharmacokinetics of cimetidine and metabolites in a neonate. <i>Drug Intell Clin Pharm.</i> 1985a;19(3):203-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/3884305/pubmed" id="3884305" target="_blank">3884305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4020559">
<a name="4020559"></a>Lloyd CW, Martin WJ, Taylor BD, et al. Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. <i>J Pediatr.</i> 1985b;107(2):295-300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/4020559/pubmed" id="4020559" target="_blank">4020559</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Penston J and Wormsley G, “Adverse Reactions and Interactions With H<sub>2</sub>-Receptor Antagonists,” <i>Med Toxicol Adverse Drug Exp</i>, 1986, 1(3):192-216.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3734359">
<a name="3734359"></a>Potter HP Jr, Byrne EB, Lebovitz S. Fever after cimetidine and ranitidine. <i>J Clin Gastroenterol</i>. 1986;8(3 Pt 1):275-276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/3734359/pubmed" id="3734359" target="_blank">3734359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12635418">
<a name="12635418"></a>Richter JE. Gastroesophageal reflux disease during pregnancy. <i>Gastroenterol Clin North Am</i>. 2003;32(1):235-261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/12635418/pubmed" id="12635418" target="_blank">12635418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470322">
<a name="29470322"></a>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(3):516-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/29470322/pubmed" id="29470322" target="_blank">29470322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7011006">
<a name="7011006"></a>Sawyer D, Conner CS, and Scalley, “Cimetidine: Adverse Reactions and Acute Toxicity,” <i>Am J Hosp Pharm</i>, 1981, 38(2):188-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/7011006/pubmed" id="7011006" target="_blank">7011006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7941209">
<a name="7941209"></a>Seshadri P, Emerson L, Morales A. Cimetidine in the treatment of interstitial cystitis. <i>Urology</i>. 1994;44(4):614-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/7941209/pubmed" id="7941209" target="_blank">7941209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6418428">
<a name="6418428"></a>Somogyi A and Gugler R, “Clinical Pharmacokinetics of Cimetidine,” <i>Clin Pharmacokinet</i>, 1983, 8(6):463-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/6418428/pubmed" id="6418428" target="_blank">6418428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3301148">
<a name="3301148"></a>Somogyi A and Muirhead M, “Pharmacokinetic Interactions of Cimetidine 1987,” <i>Clin Pharmacokinet</i>, 1987, 12(5):321-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/3301148/pubmed" id="3301148" target="_blank">3301148</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tagamet HB 200 (cimetidine) [prescribing information]. Tarrytown, NY: Medtech Products, Inc; received April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22157140">
<a name="22157140"></a>Terrin G, Passariello A, De Curtis M, et al, "Ranitidine Is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns," <i>Pediatrics</i>, 2012, 129(1):40-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/22157140/pubmed" id="22157140" target="_blank">22157140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11167643">
<a name="11167643"></a>Thilagarajah R, Witherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. <i>BJU Int</i>. 2001;87(3):207-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/11167643/pubmed" id="11167643" target="_blank">11167643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6867697">
<a name="6867697"></a>Thomson RB, Attenburrow AA, Goel KM. Cimetidine in primary duodenal ulcer in children. <i>Scott Med J</i>. 1983;28(2):164-167. doi: 10.1177/003693308302800214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/6867697/pubmed" id="6867697" target="_blank">6867697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16222731">
<a name="16222731"></a>Tomassetti P, Campana D, Piscitelli L, et al. Treatment of Zollinger-Ellison syndrome. <i>World J Gastroenterol</i>. 2005;11(35):5423-5432. doi:10.3748/wjg.v11.i35.5423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/16222731/pubmed" id="16222731" target="_blank">16222731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1360044">
<a name="1360044"></a>Van Acker BA, Koomen GC, Koopman MG, de Waart DR, Arisz L. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. <i>Lancet</i>. 1992;340(8831):1326-1329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/1360044/pubmed" id="1360044" target="_blank">1360044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19745761">
<a name="19745761"></a>Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). <i>J Pediatr Gastroenterol Nutr</i>. 2009;49(4):498-547. doi: 10.1097/MPG.0b013e3181b7f563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/19745761/pubmed" id="19745761" target="_blank">19745761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6217424">
<a name="6217424"></a>Watson AJ, Dalbow MH, Stachura I, et al. Immunologic studies in cimetidine-induced nephropathy and polymyositis. <i>N Engl J Med</i>. 1983;308(3):142-145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/6217424/pubmed" id="6217424" target="_blank">6217424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weinhouse.1">
<a name="Weinhouse.1"></a>Weinhouse GL. Stress ulcers in the intensive care unit: diagnosis, management, and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13156 Version 414.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
